Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.36 |
| ▸ | ALDH3A1 | P30838 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5485625 | 0.83 | FGFR1 (0.46) | FGFR1HTTALDH3A1POLBNOD1 | |
| SCHEMBL830432 | 0.77 | ALDH3A1 (0.57) | HTTALDH3A1POLBNOD1L3MBTL1 | |
| SCHEMBL6095796 | 0.76 | FGFR1 (0.43) | FGFR1CA12CA2CA9CA14 | |
| SCHEMBL6668410 | 0.76 | FGFR1 (0.43) | FGFR1CA12CA2CA9CA14 | |
| SCHEMBL4059255 | 0.72 | FGFR1 (0.53) | FGFR1LTA4HTGFBR1 | |
| SCHEMBL7167915 | 0.70 | CHRM1 (0.41) | FGFR1HTTALDH3A1POLBNOD1 | |
| SCHEMBL24668966 | 0.69 | ALDH3A1 (0.39) | FGFR1HTTALDH3A1POLBNOD1 | |
| SCHEMBL21992434 | 0.69 | DDB1 (0.42) | FGFR1HTTALDH3A1TSHRCA2 | |
| SCHEMBL5030414 | 0.69 | FGFR1 (0.46) | FGFR1HTTL3MBTL1TSHRLTA4H | |
| SCHEMBL6096608 | 0.69 | AHCY (0.43) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312434-A1 | PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-7098221-B2 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050282854-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-12-22 | — | — | US | disclosed |
| US-6969722-B2 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-11-29 | — | — | US | disclosed |
| US-6903113-B2 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-07 | — | — | US | disclosed |
| US-6878719-B2 | Sulfonamido substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20050032829-A1 | Process for imidazo[4,5-c]pyridin-4-amines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-02-10 | — | — | US | disclosed |
| US-20040186128-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-23 | — | — | US | disclosed |
| EP-1453829-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1451187-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2004-09-01 | — | — | EP | disclosed |
| EP-1343783-A2 | SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030162806-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-28 | — | — | US | disclosed |
| WO-2003050118-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003050117-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003050119-A2 | UREA SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-6545016-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6545017-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6525064-B1 | Immune response modifiers; can induce the biosynthesis of various cytokines; | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-20020107262-A1 | SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-08 | — | — | US | disclosed |
| WO-2002046194-A2 | SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186128-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | FGFR1 771/4885HTT 4679/4885ALDH3A1 1767/4885 |
| US-20080312434-A1 | PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES | PAICS, HTR4, PNPO | FGFR1 2503/4885HTT 2068/4885ALDH3A1 2189/4885 |
| US-20050282854-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | FGFR1 771/4885HTT 4679/4885ALDH3A1 1767/4885 |
| US-20020107262-A1 | SUBSTITUTED IMIDAZOPYRIDINES | IRF3, IFNG, EIF2AK2 | FGFR1 863/4885HTT 4635/4885ALDH3A1 2259/4885 |
| US-20050032829-A1 | Process for imidazo[4,5-c]pyridin-4-amines | PAICS, HTR4, PNPO | FGFR1 2503/4885HTT 2068/4885ALDH3A1 2189/4885 |
| US-20030162806-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | FGFR1 771/4885HTT 4679/4885ALDH3A1 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.